Non‐invasive assessments for liver fibrosis: The crystal ball we long for
Open Access
- 30 January 2018
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 33 (5) , 1009-1015
Abstract
Non‐invasive assessment of liver fibrosis has been one of the most rapidly advancing fields in hepatology in the last decade. Progressive liver fibrosis results in cirrhosis, hepatocellular carcinoma (HCC), and various liver‐related complications in essentially all chronic liver diseases. Assessment of liver fibrosis allows clinicians to determine the prognosis, need of treatment, disease progression, and response to treatment in patients with chronic liver disease. Liver biopsy has been the gold standard in last few decades and most adopted diagnostic tool in clinical trials. Nonetheless, it is impractical to apply the test in a large number of patients or to do it serially. Hence, various non‐invasive assessments have been developed and adopted in some international management guidelines. Liver stiffness measurement (LSM) with transient elastography is one of the most widely validated non‐invasive assessments for liver fibrosis. It is an accurate and reproducible method to predict advanced fibrosis in chronic hepatitis B. Using transient elastography, it is possible to perform repeated liver fibrosis assessments on a large number of asymptomatic patients. The key challenge of his tool is the confounding effect of alanine aminotransferase (ALT) level, such that decrease in LSM may only reflect ALT normalization, hence not accurate enough to indicate regression of liver fibrosis. This may be partially handled by combining LSM with a serum‐based formula, which is independent of ALT such as the Forns index and enhanced liver fibrosis test. An LSM‐based HCC risk score is useful to prioritize patients for HCC surveillance.Keywords
This publication has 79 references indexed in Scilit:
- Transient elastography: Kill two birds with one stone?World Journal of Hepatology, 2013
- Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient DataPLOS ONE, 2012
- A New Combination of Blood Test and Fibroscan for Accurate Non-Invasive Diagnosis of Liver Fibrosis Stages in Chronic Hepatitis CAmerican Journal of Gastroenterology, 2011
- Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver diseaseGut, 2010
- Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis CLiver International, 2008
- FibroMeters: a family of blood tests for liver fibrosisGastroentérologie Clinique Et Biologique, 2008
- FIB-4Hepatology, 2007
- The NAFLD fibrosis scoreHepatology, 2007
- Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis CHepatology, 2007
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003